Zi Ran Tong

Systematic review and meta-analysis of 29 randomised controlled trials (3,206 patients) of Chinese patent medicines containing pyrite for fracture. Pooled results favoured the pyrite-containing medicine for total effective rate (17 trials, OR 0.30, 95% CI 0.23-0.39), callus growth rate (7 trials, OR 0.18, 95% CI 0.12-0.27), bone union, oedema resolution time and VAS pain, with lower reported postoperative complication rates. The authors themselves stress heavy caveats: heterogeneity was high (I2 > 50%) across most outcomes, 25 of 29 trials carried "some concern" and 4 a high risk of bias, none blinded participants or outcome assessors, and all were of Chinese patent medicines containing several ingredients rather than pyrite alone. They also note explicitly that heavy metals including arsenic and lead in mineral drugs restrict their use and account for the thin safety literature.

Systematic review of 36 studies (23 randomised controlled trials, 13 case reports) of externally applied pyrite-containing patent medicines, undertaken explicitly because of concern about heavy-metal accumulation from oral use. Total effective rates favoured the pyrite preparations across anorectal, orthopaedic, obstetric-gynaecological and dermatological indications. The review is a narrative synthesis of effective-rate data from mostly Chinese-language trials with no meta-analysis and no independent risk-of-bias grading reported, so it is best read as a mapping of where external pyrite is used rather than as evidence of efficacy.

Thirty-two male Sprague-Dawley rats with surgical tibial defects received aqueous extracts of raw or processed pyritum at 1.5 g/kg orally for 42 days. Both extracts improved radiographic healing and raised whole-tibia bone mineral density and callus calcium, phosphorus and magnesium content versus water control, and drug-containing serum from both raised osteoblast alkaline phosphatase and collagen type I mRNA with increased phosphorylated Smad2/3, implicating TGF-beta1/Smad signalling. The healing effect of the processed drug was significantly greater than that of the raw drug, which is the experimental counterpart of the classical insistence on calcining before internal use. No arsenic or lead measurements were reported in the animals.

Mineralogical and cell-based comparison of raw and processed pyrite. Calcination and vinegar quenching left the material fragile and shifted the main phase from FeS2 to Fe7S8; in the resulting decoction iron and zinc concentrations rose while arsenic fell. Serum containing processed pyrite raised osteoblast alkaline phosphatase activity and increased the number and area of mineralised nodules more than serum containing raw pyrite. This is the primary source for the claim that the traditional processing step is simultaneously an efficacy step and an arsenic-reduction step.

Pyrite was processed at temperatures up to 850 degrees C for up to five heat-and-vinegar-quench cycles, and metal extraction was measured from each product. Higher temperature and more cycles promoted conversion to hematite and lowered both the toxic-metal content of the solid and the concentrations extracted into solution, but the relationship with cycle number at a fixed temperature was inconsistent. The authors conclude that heating temperature is the dominant variable and that pyrite should be processed at the highest feasible temperature specifically to diminish arsenic and lead.

Process-development study proposing vacuum roasting as an alternative to open-fire calcination and vinegar quenching for pyritum, motivated by the heavy-metal load of commercially processed material. Vacuum roasting at 1000 degrees C for 60 minutes was reported to eliminate arsenic and to remove about 70 percent of lead, while avoiding the sulfur dioxide emissions of conventional calcination. This is a materials-processing paper with no pharmacological or clinical outcome data, but it is direct evidence that arsenic and lead are present in market-grade processed pyritum at levels worth engineering away.